



FOR IMMEDIATE RELEASE

**Lee's Pharm announces that China registration study of
Trazodone Hydrochloride Tablets for depression has met its primary endpoint**

(Hong Kong 2th Oct 2013) – Lee's Pharmaceutical Holdings Limited (Main Board Stock: 0950: Website: www.leespharm.com) today announced that China registration study of Trazodone for depression has met its primary endpoint. Trazodone (Trittico®) is a product licensed from Angelini of Italy and the registration study is to evaluate the efficacy and safety of Trazodone for treatment of depression in Chinese population.

This multi-centers, randomized, double-blinded, paralleled and placebo-controlled clinical study was conducted at 13 clinical centers located in Changsha, Beijing, Shanghai, Nanjing, Hangzhou, Tianjin and Guangzhou etc; and led by The Second Xiangya Hospital of Central South University in Changsha, Hunan. The study had enrolled a total of 382 patients during the period between March 2012 and June 2013.

The primary efficacy endpoint of the study is the measurement of change from baseline in Hamilton Depression Rating Scale ("HAMD") at visit 6/final visit. The results show that, after 6 weeks treatment in patients with depression, the decrease of HAMD value in Trazodone treatment group is 11.10 and in the placebo group is 8.61, the different between treatment group and placebo group reaching statistically significance (11.10 vs. 8.61, $P < 0.001$).

"We are thrilled of reaching the primary efficacy endpoint in this China registration study of Trazodone. The successful conclusion of the study will make Trittico® registration enable in China and submission of the Import Drug License application is targeted in the fourth quarter of this year," said Dr. Benjamin Li, Chief Executive Officer of the Company. "Depression prevalence has been increased significantly in China during the last 20 years. With Trittico®, Lee's will be in position to broaden the treatment option for Chinese patients suffered from depression."

Trazodone, a potent postsynaptic serotonin 5-HT_{2A} receptor antagonist and a moderate inhibitor of serotonin reuptake, is the original member of the SARIs (serotonin-2 antagonist/reuptake inhibitors) group of antidepressants. The targeted indication is depression with or without anxiety, including sleep disorders in depressed patients. The product has been widely prescribed since its original launch in 1990's by its originator Angelini. Trittico® is a sustained-release formulation newly developed by Angelini with better patient compliance.



FOR IMMEDIATE RELEASE

About Angelini

Angelini, a privately owned, international group with Italian roots, is leader in the healthcare and wellbeing market in the pharmaceutical and mass market sectors. Angelini was founded in Italy at the beginning of the 20th Century. It is a medium-sized group with branches in 18 countries and worldwide product distribution. In the pharmaceutical sector, Angelini focuses mainly on pain relief, inflammation, CNS, paediatrics, cold & flu, oralcare & sorethroat, gynecology, disinfection. Angelini is one of the top four pharmaceutical companies in Italy by sales volume. Today the Angelini Group, led by its chairman Francesco Angelini, the founder's grandson, is a major international corporation operating both in Italy and abroad and employing around 3,300 people, with total annual sales of approximately 1,2 billion euros.

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com